Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
Holding OGN?
Track your performance easily
OGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.84 - $23.10
Previous Close$17.16
Volume1.56M
Average Volume (3M)1.93M
Market Cap
$4.42B
Enterprise Value$12.37B
Total Cash (Recent Filing)$704.00M
Total Debt (Recent Filing)$8.66B
Price to Earnings (P/E)4.4
Beta1.01
Next Earnings
Oct 31, 2024EPS Estimate
$0.9Last Dividend Ex-Date
Aug 16, 2024Dividend Yield6.53%
Share Statistics
EPS (TTM)3.89
Shares Outstanding257,473,477
10 Day Avg. Volume1,814,335
30 Day Avg. Volume1,929,420
Standard Deviation0.13
R-Squared0.11
Alpha-0.00710
Financial Highlights & Ratios
Price to Book (P/B)30.64
Price to Sales (P/S)0.70
Price to Cash Flow (P/CF)3.30
P/FCF Ratio2.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit3.30
Enterprise Value/Ebitda14.27
Forecast
1Y Price Target
$21.17Price Target Upside21.25% Upside
Rating ConsensusHold
Number of Analyst Covering8
Organon News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceOGN remains on track to generate ~$1.0bn in FCF, and remains on track to achieve leverage targets of ~4.0x net debt/EBITDA ratio by year-end (vs. current levels of ~4.1x, on pace with FY23).
Market ExpansionOGN is diversifying into a US branded area (immunology/dermatology) outside of where they have a meaningful presence.
Product DevelopmentWithin the Women's Health franchise, we would note the recent positive readout of Nexplanon's 5-year efficacy data, with regulatory filings in the US, EU, and UK anticipated on the forward.
Bears Say
Financial PerformanceThe transaction is expected to be moderately dilutive to adjusted EBITDA in 2025.
Market CompetitionThere remains a pathway for generics to enter the market in the late 2020s with a different device and three year indication.
Stock PerformanceOGN shares underperformed on a relative basis (-6% vs. +2% for the SPX), as there was some expectation for potential continuation of momentum and a guidance increase for FY24 following the company's strong 1Q results.
---
Ownership Overview
0.19% Insiders
22.29% Mutual Funds
2.04% Other Institutional Investors
50.17% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OGN FAQ
What was Organon’s price range in the past 12 months?
Organon lowest stock price was $10.84 and its highest was $23.10 in the past 12 months.
What is Organon’s market cap?
Currently, no data Available
When is Organon’s upcoming earnings report date?
Organon’s upcoming earnings report date is Oct 31, 2024 which is in 2 days.
How were Organon’s earnings last quarter?
Organon released its earnings results on Aug 06, 2024. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.076 by $0.044.
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Undervalued.
Does Organon pay dividends?
Organon pays a Quarterly dividend of $0.28 which represents an annual dividend yield of 6.53%. See more information on Organon dividends here
What is Organon’s EPS estimate?
Organon’s EPS estimate is $0.9.
How many shares outstanding does Organon have?
Organon has 257,473,480 shares outstanding.
What happened to Organon’s price movement after its last earnings report?
Organon reported an EPS of $1.12 in its last earnings report, beating expectations of $1.076. Following the earnings report the stock price went down -7.634%.
Which hedge fund is a major shareholder of Organon?
Among the largest hedge funds holding Organon’s share is Slate Path Capital LP. It holds Organon’s shares valued at 112M.
---
Organon Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$21.17 (21.25% Upside)
$21.17 (21.25% Upside)
Blogger Sentiment
Bullish
OGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 127.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.70%
Trailing 12-Months
Company Description
Organon
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
---
OGN Company Deck
---
OGN Earnings Call
Q2 2024
0:00 / 0:00
---
OGN Stock 12 Month Forecast
Average Price Target
$21.17
▲(21.25% Upside)
Technical Analysis
Heron Therapeutics
―
Supernus Pharmaceuticals
―
Perrigo Company
―
Pacira Pharmaceuticals
―
Best Analysts Covering OGN
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+7.74%
reiterated a sell rating 3 months ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +7.74% per trade.
---